Halozyme Therapeutics Inc (HALO)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	444,091	392,467	337,293	318,802	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139
Total stockholders’ equity	US$ in thousands	363,821	452,703	289,424	177,808	83,808	249,181	151,033	65,850	169,798	96,991	293,171	260,256	196,953	281,674	119,748	67,595	151,047	98,988	105,577	58,042
ROE		122.06%	86.69%	116.54%	179.30%	336.00%	101.90%	154.74%	275.83%	119.04%	217.75%	124.89%	167.11%	204.47%	145.24%	191.00%	241.26%	85.46%	21.74%	-37.60%	-138.07%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $444,091K ÷ $363,821K
= 122.06%

Halozyme Therapeutics Inc's return on equity (ROE) has shown significant fluctuations over the analyzed period. The ROE was negative in the first two quarters of 2020, indicating that the company was generating a net loss in relation to its shareholders' equity during that period.

However, there was a notable turnaround in the third quarter of 2020, with the ROE turning positive and increasing steadily over the following quarters. This trend continued into 2021 and 2022, with ROE reaching peak levels in March 2023 and December 2023, indicating that the company was generating substantial profits relative to the shareholders' equity during those periods.

Subsequently, there was a slight decrease in ROE in June 2023, followed by a more significant decline in the following quarters, although the ROE remained at healthy levels compared to the initial negative values observed in 2020.

Overall, the trend in Halozyme Therapeutics Inc's ROE demonstrates an improvement in the company's profitability and efficiency in generating returns for its shareholders. However, the fluctuations in ROE also suggest some variability in the company's financial performance over the analyzed period.